Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 1/20 | 0.51 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.45 |
| ▸ | GSK3B | P49841 | 4/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.45 |
| ▸ | CLK2 | P49760 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.45 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.45 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5214451 | 0.90 | CSNK1D (0.51) | CSNK1DMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5726060 | 0.89 | CSNK1D (0.51) | CSNK1DEIF2AK2MAPK13MAPK12MAPK11 | |
| SCHEMBL5220849 | 0.88 | EIF2AK2 (0.50) | EIF2AK2MAPK10MAPK8MAPK9GSK3B | |
| SCHEMBL5890649 | 0.87 | CSNK1D (0.51) | CSNK1DEIF2AK2MAPK13MAPK12MAPK11 | |
| SCHEMBL6496045 | 0.86 | CSNK1D (0.51) | CSNK1DMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5891079 | 0.86 | CSNK1D (0.50) | CSNK1DEIF2AK2MAPK13MAPK12MAPK11 | |
| SCHEMBL5724993 | 0.85 | CSNK1D (0.48) | CSNK1DMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5890640 | 0.85 | CSNK1D (0.49) | CSNK1DEIF2AK2MAPK13MAPK12MAPK11 | |
| SCHEMBL6489239 | 0.84 | ADORA1 (0.44) | CSNK1DEIF2AK2MAPK14CDK4MAPK10 | |
| SCHEMBL5726350 | 0.83 | CSNK1D (0.49) | CSNK1DEIF2AK2MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423389-B1 | PYRAZOLO-PYRIDINES FOR THE TREATMENT OF HERPES INFECTIONS | SMITHKLINE BEECHAM CORP (US) | 2007-06-06 | — | — | EP | disclosed |
| US-7034030-B2 | Pyralopyridines, process for their preparation and use as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-7030134-B2 | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-18 | — | — | US | disclosed |
| US-20060058319-A1 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | ALBERTI MICHAEL J | 2006-03-16 | — | — | US | disclosed |
| US-6962914-B2 | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050192303-A1 | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds | GUDMUNDSSON KRISTJAN (US) | 2005-09-01 | — | — | US | disclosed |
| EP-1385847-B1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES | SMITHKLINE BEECHAM CORP (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
| US-20040142941-A1 | Therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142941-A1 | Therapeutic compounds | PCSK9, ABCB1, ABCB11 | CSNK1D 466/4885EIF2AK2 3551/4885MAPK13 4380/4885 |
| US-20060058319-A1 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | CYP3A5, CYP3A4, CYP3A7 | CSNK1D 542/4885EIF2AK2 3578/4885MAPK13 1593/4885 |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | QDPR, DPYD, ENTPD5 | CSNK1D 2789/4885EIF2AK2 57/4885MAPK13 2280/4885 |
| US-20050192303-A1 | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds | DPYD, TYMP, P2RY4 | CSNK1D 479/4885EIF2AK2 1588/4885MAPK13 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.